Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes mellitus: A protocol for systematic review and network meta-analysis

Review question / Objective: This study is to systematically evaluate the efficacy and safety of hypoglycemic agents for the treatment of non-alcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM).The network meta-analysis will be used to indirectly compare different hypoglycemic agents to find out the optimal treatment plan for NAFLD with T2DM and to provide evidence-based bias for clinical treatments decision-making.Only randomized controlled trial will be included.Condition being studied: NAFLD is the most common cause of chronic liver disease in Western countries, and strongly associated with T2DM.Several studies have shown that hypoglycemic agents are effective for NAFLD combined with T2DM.However, there is still no relevant systematic study on the efficacy and safety of those various hypoglycemic agents in the treatment of NAFLD combined with T2DM.Therefore, there is no strong evidence to support which drug is appropriate for patients, the newer, the better; or the more expensive, the better?In this study, the efficacy and safety of multiple hypoglycemic agents will be compared to provide a bias for patients to selectively take hypoglycemic agents.